The Life Sciences team advised Bicara Therapeutics in its oversubscribed $165 million Series C financing.

The financing was co-led by Braidwell LP and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with additional new investors including Deerfield Management, Fairmount, Aisling Capital and a leading biotechnology investor associated with one of the largest alternative asset managers. All existing Series B investors also participated in the round.

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators.

The Goodwin team was led by Gaby Morales-Rivera, Amarilice Young, Frank Qin, Isabelle Anselmo and Kingsley Taft, with invaluable assistance from Alexandra Singer, Jacob Osborn, Gozde Guckaya, Grace Wirth, Caroline Galiatsos, Mark Burnett and Patricia Robichaud.

For more details, read the press release and coverage in Endpoints News and Fierce Biotech.